February 23, 2021
4 min read
Disclosures: Anderson reports personal fees from and advisory board roles with Amgen, Bristol Myers Squibb, Gilead, Janssen, Pfizer, Precision Biosciences, Sanofi-Aventis and Takeda. Please see the guidelines for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
Back to Healio
New guidance that emerged from an FDA and American Association for Cancer Research joint workshop addresses the underrepresentation of African Americans in multiple myeloma clinical trials.
Published in Blood Cancer Discovery, the recommendations are aimed at eliminating racial bias by including more African Americans — who are twice as likely as white individuals to be diagnosed with myeloma — in clinical trials. The recommendations also support using real-world data to better understand the effects of antimyeloma agents among African American patients…